KRAS G12C Mutation: An Emerging Biomarker for NSCLC

Educational objectives:

 

  -  Review the evolving NSCLC biomarker landscape, demographics

      and histopathology

  -  Raise awareness that KRAS G12C is the most prevalent emerging

      molecular target in NSCLC

  -  Discuss the available methods and clinical guideline

      recommendations for biomarker testing at diagnosis of NSCLC

 

Presented by:

 

Fesko, Yuri, MD, Chief Clinical Officer, Oncology Quest Diagnostics, Secaucus, New Jersey

 

Hooper, Kari, MD; Pathologist, AmeriPath®/Quest Diagnostics; Department Chair, Integris Baptist Medical Center Oklahoma City, Oklahoma

Date:

Jan 04, 2021

Presenter(s):

Kari Hooper, and Yuri Fesko